HealthDay News — Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have been reported. The review covers Beyfortus (from Sanofi ...
As an FDA official said that the agency has evidence that links COVID vaccines to the deaths of at least 10 children, the U.S ...
U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective ...
In this morning's Pharmalittle roundup, we're reading about FDA scrutiny of RSV therapies, an AI tool for clinical trials, ...
FDA reexamine infant RSV therapies with Sanofi, AstraZeneca, and Merck amid safety concerns and data review under new FDA leadership.
Merck (NYSE:MRK) has received FDA approval for Enflonsia, a prophylactic antibody therapy designed to protect infants from respiratory syncytial virus (RSV) in a market dominated by Beyfortus, a rival ...
U.S. regulators are reexamining infant RSV antibody treatments as safety questions surface, prompting new FDA scrutiny of ...
3don MSNOpinion
FDA launches safety review of two RSV drugs for infants as Kennedy scrutinizes immunizations
The Food and Drug Administration has launched a safety review of two approved RSV drugs for infants, the latest immunizations ...
A wall showing a Merck & Co. logo in Kenilworth, New Jersey This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive ...
Please provide your email address to receive an email when new articles are posted on . Clesrovimab is a monoclonal antibody that protects against RSV subtypes A and B. The FDA set a PDUFA date for ...
The agency also is reviewing safety of immunizations for RSV, according to manufacturers of the therapies who have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback